nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—CYP1A2—Methimazole—Graves' disease	0.348	0.526	CbGbCtD
Leflunomide—CYP2C9—Methimazole—Graves' disease	0.313	0.474	CbGbCtD
Leflunomide—Traumatic liver injury—Propylthiouracil—Graves' disease	0.0219	0.0823	CcSEcCtD
Leflunomide—Interstitial pneumonia—Propylthiouracil—Graves' disease	0.0169	0.0634	CcSEcCtD
Leflunomide—Neuritis—Methimazole—Graves' disease	0.0128	0.0483	CcSEcCtD
Leflunomide—Interstitial lung disease—Propylthiouracil—Graves' disease	0.0115	0.0433	CcSEcCtD
Leflunomide—Neuritis—Propylthiouracil—Graves' disease	0.0109	0.041	CcSEcCtD
Leflunomide—Skin ulcer—Propylthiouracil—Graves' disease	0.0105	0.0394	CcSEcCtD
Leflunomide—DHODH—pituitary gland—Graves' disease	0.0103	0.141	CbGeAlD
Leflunomide—DHODH—adipose tissue—Graves' disease	0.0103	0.14	CbGeAlD
Leflunomide—Liver injury—Propylthiouracil—Graves' disease	0.00968	0.0364	CcSEcCtD
Leflunomide—DHODH—thyroid gland—Graves' disease	0.00891	0.122	CbGeAlD
Leflunomide—PTK2B—connective tissue—Graves' disease	0.0085	0.116	CbGeAlD
Leflunomide—Vasculitis—Propylthiouracil—Graves' disease	0.00835	0.0314	CcSEcCtD
Leflunomide—Lymphadenopathy—Methimazole—Graves' disease	0.00815	0.0307	CcSEcCtD
Leflunomide—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00693	0.0261	CcSEcCtD
Leflunomide—Hepatic failure—Propylthiouracil—Graves' disease	0.00658	0.0248	CcSEcCtD
Leflunomide—PTK2B—adipose tissue—Graves' disease	0.00652	0.089	CbGeAlD
Leflunomide—PTK2B—thyroid gland—Graves' disease	0.00564	0.077	CbGeAlD
Leflunomide—AHR—pituitary gland—Graves' disease	0.00538	0.0735	CbGeAlD
Leflunomide—AHR—adipose tissue—Graves' disease	0.00536	0.0732	CbGeAlD
Leflunomide—Neuropathy peripheral—Methimazole—Graves' disease	0.00525	0.0198	CcSEcCtD
Leflunomide—Jaundice—Methimazole—Graves' disease	0.00522	0.0197	CcSEcCtD
Leflunomide—Agranulocytosis—Methimazole—Graves' disease	0.005	0.0188	CcSEcCtD
Leflunomide—Hepatitis—Methimazole—Graves' disease	0.00481	0.0181	CcSEcCtD
Leflunomide—AHR—thyroid gland—Graves' disease	0.00464	0.0633	CbGeAlD
Leflunomide—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00447	0.0168	CcSEcCtD
Leflunomide—Jaundice—Propylthiouracil—Graves' disease	0.00444	0.0167	CcSEcCtD
Leflunomide—Agranulocytosis—Propylthiouracil—Graves' disease	0.00425	0.016	CcSEcCtD
Leflunomide—Alopecia—Methimazole—Graves' disease	0.00425	0.016	CcSEcCtD
Leflunomide—Haemoglobin—Propylthiouracil—Graves' disease	0.00411	0.0155	CcSEcCtD
Leflunomide—Haemorrhage—Propylthiouracil—Graves' disease	0.00409	0.0154	CcSEcCtD
Leflunomide—Hepatitis—Propylthiouracil—Graves' disease	0.00409	0.0154	CcSEcCtD
Leflunomide—Vertigo—Methimazole—Graves' disease	0.00376	0.0142	CcSEcCtD
Leflunomide—Leukopenia—Methimazole—Graves' disease	0.00375	0.0141	CcSEcCtD
Leflunomide—Alopecia—Propylthiouracil—Graves' disease	0.00361	0.0136	CcSEcCtD
Leflunomide—Myalgia—Methimazole—Graves' disease	0.00357	0.0134	CcSEcCtD
Leflunomide—Arthralgia—Methimazole—Graves' disease	0.00357	0.0134	CcSEcCtD
Leflunomide—Dysgeusia—Propylthiouracil—Graves' disease	0.00349	0.0131	CcSEcCtD
Leflunomide—Thrombocytopenia—Methimazole—Graves' disease	0.00335	0.0126	CcSEcCtD
Leflunomide—Vertigo—Propylthiouracil—Graves' disease	0.0032	0.012	CcSEcCtD
Leflunomide—Leukopenia—Propylthiouracil—Graves' disease	0.00319	0.012	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00311	0.0117	CcSEcCtD
Leflunomide—Paraesthesia—Methimazole—Graves' disease	0.00307	0.0115	CcSEcCtD
Leflunomide—Arthralgia—Propylthiouracil—Graves' disease	0.00303	0.0114	CcSEcCtD
Leflunomide—Myalgia—Propylthiouracil—Graves' disease	0.00303	0.0114	CcSEcCtD
Leflunomide—Dyspepsia—Methimazole—Graves' disease	0.00301	0.0113	CcSEcCtD
Leflunomide—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00285	0.0107	CcSEcCtD
Leflunomide—Urticaria—Methimazole—Graves' disease	0.00271	0.0102	CcSEcCtD
Leflunomide—Body temperature increased—Methimazole—Graves' disease	0.0027	0.0102	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00265	0.00996	CcSEcCtD
Leflunomide—Paraesthesia—Propylthiouracil—Graves' disease	0.00261	0.00982	CcSEcCtD
Leflunomide—Dyspepsia—Propylthiouracil—Graves' disease	0.00256	0.00962	CcSEcCtD
Leflunomide—Pruritus—Methimazole—Graves' disease	0.00242	0.0091	CcSEcCtD
Leflunomide—Urticaria—Propylthiouracil—Graves' disease	0.00231	0.00869	CcSEcCtD
Leflunomide—Body temperature increased—Propylthiouracil—Graves' disease	0.0023	0.00864	CcSEcCtD
Leflunomide—Vomiting—Methimazole—Graves' disease	0.00217	0.00818	CcSEcCtD
Leflunomide—Rash—Methimazole—Graves' disease	0.00215	0.00811	CcSEcCtD
Leflunomide—Dermatitis—Methimazole—Graves' disease	0.00215	0.0081	CcSEcCtD
Leflunomide—Headache—Methimazole—Graves' disease	0.00214	0.00806	CcSEcCtD
Leflunomide—ABCG2—pituitary gland—Graves' disease	0.00209	0.0285	CbGeAlD
Leflunomide—ABCG2—adipose tissue—Graves' disease	0.00208	0.0284	CbGeAlD
Leflunomide—Pruritus—Propylthiouracil—Graves' disease	0.00206	0.00774	CcSEcCtD
Leflunomide—Nausea—Methimazole—Graves' disease	0.00203	0.00764	CcSEcCtD
Leflunomide—Vomiting—Propylthiouracil—Graves' disease	0.00185	0.00695	CcSEcCtD
Leflunomide—Rash—Propylthiouracil—Graves' disease	0.00183	0.00689	CcSEcCtD
Leflunomide—Dermatitis—Propylthiouracil—Graves' disease	0.00183	0.00689	CcSEcCtD
Leflunomide—Headache—Propylthiouracil—Graves' disease	0.00182	0.00685	CcSEcCtD
Leflunomide—ABCG2—thyroid gland—Graves' disease	0.0018	0.0246	CbGeAlD
Leflunomide—CYP1A2—thyroid gland—Graves' disease	0.00173	0.0236	CbGeAlD
Leflunomide—Nausea—Propylthiouracil—Graves' disease	0.00173	0.00649	CcSEcCtD
